AKBA | tickerfilter.com

Fundamental analysis

45%

Profitability 44%

Dept financing 41%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.79%

1 Month

-9.42%

3 Months

-18.83%

6 Months

-57.77%

1 Year

-32.61%

2 Year

-21.88%

Key data

Stock price

$1.25

P/E Ratio

0.00

DAY RANGE

$1.22 - $1.28

EPS

-$0.02

52 WEEK RANGE

$1.14 - $4.08

52 WEEK CHANGE

-$34.90

MARKET CAP

427.239 M

YIELD

N/A

SHARES OUTSTANDING

267.879 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

3.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,578,173

AVERAGE 30 VOLUME

$3,826,611

Company detail

CEO: John P. Butler
Region: US
Website: akebia.com
Employees: 430
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.

AKBA - Akebia Therapeutics, Inc.